Loading patent…
AssigneeChigenovo Co., Ltd
InventorsLiping Yang, Shaohong Chen, Ruixuan Jia, Tianfu Zhang, Fan Zhang, Qiaoli Zeng, Saichao He, Tianyong Shi, Dandan Hao, Shangwei Jiang, Hongjie PEI, Xudong Wang, Luying Zeng
Estimating the term…
The present application relates to the use of CYP4V2 and RdCVF in the manufacture of a medicament for treating, alleviating, and/or preventing a disease or disorder associated with retinal pigment epithelium (RPE) atrophy. The present application also relates to an isolated nucleic acid molecule comprising a polynucleotide encoding CYP4V2 and a polynucleotide encoding RdCVF. The present application also relates to an amino acid sequence encoded by the isolated nucleic acid molecule, a vector comprising the isolated nucleic acid molecule, and a cell comprising the nucleic acid or the vector as well as use thereof in the manufacture of a medicament for treating, alleviating, and/or preventing a disease or disorder associated with retinal pigment epithelium (RPE) atrophy.
Use of CYP4V2 and RdCVF in the manufacture of a medicament for treating, alleviating, and/or preventing a disease or disorder associated with retinal pigment epithelium (RPE) atrophy.
A vector combination for treating, alleviating, and/or preventing a disease or disorder associated with retinal pigment epithelium (RPE) atrophy, comprising a first vector and a second vector, wherein the first vector comprises a polynucleotide encoding CYP4V2, and the second vector comprises a polynucleotide encoding RdCVF.
One or more isolated nucleic acid molecule(s) comprising a) a polynucleotide encoding CYP4V2, and b) a polynucleotide encoding RdCVF.
Dependencies are inferred from the claim text.